PROS1 and COVID-19: This is the first study to assess the immunogenicity, reactogenicity and safety of ID administration of an inactivated COVID-19 vaccine at a full dose, which demonstrated superior antibody responses and T-cell responses against the SARS-CoV-2 M protein in adolescents who received three injections.